Julie Autmizguine , M.D. , MHS , FRCPC
    Julie Autmizguine
    Research Axis
    Infectious Diseases and Acute Care Axis
    Research Theme
    Clinical pharmacology
    CHUSJ - Centre de Recherche

    514 345-4931 #5566

    514 345-4908


    • Pediatric Infectious Disease Physician, CHU Sainte-Justine, 2014
    • Clinical Associate Professor, Departments of Pharmacology and Physiology, and Pediatrics, University of Montréal


    • Masters in Health Sciences, Duke University, 2014
    • Fellowship in clinical pharmacology, Duke Clinical Research Institute, 2014
    • Pediatric infectious disease residency, University of Montreal, 2012
    • Pediatric residency, University of Montreal, 2010
    • MD, University of Sherbrooke, 2006

    Career Summary

    Dr. Autmizguine is a pediatrician specialized in infectious diseases at the CHU Sainte-Justine. After completing a pediatric residency and a fellowship in pediatric infectious disease at Université de Montréal in 2012, Dr Autmizguine trained in clinical pharmacology at the Duke Clinical Research Institute, and received a Master’s in Health Science focused on Clinical Research in 2014.

    Her research activity focuses on pediatric clinical pharmacology. She is interested in reducing off-label prescription and increasing safety and effectiveness of drug therapies for children of all ages. More specifically, she works on dosing optimization based on pharmacokinetic modeling and simulation. Dr Autmizguine is also dedicated to improving access to pediatric drug formulations as a member of the The Rosalind & Morris Goodman Family Pediatric Formulations Centre of the CHU Sainte-Justine.

    Awards and Distinctions

    • Robert A. Harrington Excellence in Fellowship Award, Duke Clinical Research Institute, 2014
    • Training Award, Fonds Irma-Levasseur, Sainte-Justine Hospital, 2012-2014
    • Trainee Travel Grant IDweek, 2012
    • Best presentation at Saint-Justine Hospital Pediatrics Residents’ Research Day, 2012
    • IMS award, IMS Health Canada, Pharmacology, 2002
    • Valedictorian, University of Montpellier I, France, Medicine, 2000


    1. Autmizguine J, Hornik CP, Benjamin DK Jr, Brouwer KL, Hupp SR, Cohen-Wolkowiez M, Watt KM. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.  Pediatr Infect Dis J. 2016 Nov;35(11):1204-1210.
    2. Dionne A, Meloche-Dumas L, Desjardins L, Turgeon J, Saint-Cyr C, Autmizguine J, Spigelblatt L, Fournier A, Dahdah N. N-terminal pro-B-type natriuretic peptide diagnostic algorithm versus American Heart Association algorithm for Kawasaki disease. Pediatr Int. 2016 Sep 2. doi: 10.1111/ped.13154. [Epub ahead of print]
    3. Labrosse M, Levy, Autmizguine J, Gravel J. Evaluation of a New Strategy for Clean-Catch Urine in Infants. Pediatrics. 2016 Sep;138(3). pii: e20160573. doi: 10.1542/peds.2016-0573.
    4. Blanchard AC, Quach C, Autmizguine JStaphylococcal infections in infants: updates and current challenges. Clin Perinatol. 2015 Mar;42(1):119-32, ix. Review.
    5. Laverdiere M, Bow EJ, Rotstein C, Autmizguine J, Broady R, Garber G, Haider S, Hussaini T, Husain S, Ovetchkine P, Seki JT, Théorêt Y. Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol. 2014 Nov-Dec;25(6):327-43. Review.
    6. Autmizguine J, Hornik CP, Benjamin DK Jr, Laughon MM, Clark RH, Cotten CM, Cohen-Wolkowiez M, Benjamin DK, Smith PB.  Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants. Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee. Pediatrics. 2015 Jan;135(1):e117-25.
    7. Autmizguine J, Cohen-Wolkowiez M, Ilowite N; RAPPORT Investigators. Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2015 Jan;55(1):39-44.
    8. Autmizguine J, Guptill JT, Cohen-Wolkowiez M, Benjamin DK Jr, Capparelli EV. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs. 2014 Jun;74(8):891-909.  Review.
    9. Autmizguine J, Benjamin DK Jr, Smith PB, Sampson M, Ovetchkine P, Cohen-Wolkowiez M, Watt KM. Pharmacokinetic studies in infants using minimal-risk study designs. Curr Clin Pharmacol. 2014;9(4):350-8. Review.
    10. Autmizguine J, Moran C, Gonzalez D, Capparelli EV, Smith PB, Grant GA, Benjamin DK Jr, Cohen-Wolkowiez M, Watt KM. Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections. Pediatr Infect Dis J. 2014 Oct;33(10):e270-2. 
    11. Autmizguine J, Hornik C, Benjamin DK Jr, Laughon MM, Clark RH, Cotten CM, Cohen-Wolkowiez M, Benjamin DK, Smith PB on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. Anaerobic therapy and clinical outcomes in very-low-birth-weight infants with necrotizing enterocolitis. Accepted in Pediatrics
    12. Autmizguine J, Cohen-Wolkowiez M, Ilowite N for the RAPPORT investigators. Rilonacept Pharmacokinetics in Children with Systemic Juvenile Idiopathic Arthritis. J Clin Pharmacol. 2014 Jul 30.
    13. Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan J, Autmizguine J, Lewandowski A, Harper B, Watt KM, Capparelli EV, Benjamin Jr DK, Cohen-Wolkowiez M. Use of Opportunistic Clinical Data and a Population Pharmacokinetic Model to Support Dosing of Clindamycin for Premature Infants to Adolescents. Clin Pharmacol Ther. 2014 Oct;96(4):429-37
    14. Autmizguine J, Moran C, Gonzalez D, Capparelli EV, Smith PB, Benjamin DK, Cohen-Wolkowiez M, Watt KM. Vancomycin Pharmacokinetics and Cerebrospinal Fluid Exposure in Children with Cerebral Ventricular Shunt Infections. Pediatr Infect Dis J. 2014 Apr 25. [Epub ahead of print]
    15. Autmizguine J, Watt KM, Théorêt Y, Kassir N, Laferrière C, Parent S, Tapiero B, Ovetchkine P. Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infection. Pediatr Infect Dis J.2013 Jun 27.

Grow Beyond our wildest dreams

With the support of donors like you, at the heart of the Grow Beyond campaign, we are leading healthcare teams towards the opportunities offered by science and new technologies, so that every child, no matter where in Quebec, has access to the unique expertise and know-how of CHU Sainte-Justine. Together, let's join forces for their future.

Grow Beyond with us.

Contact Us

514 345-4931


© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security


Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine